Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP)

Shots:

• The P-III A4091059 study involves assessing of tanezumab (5mg,10mg) vs PBO vs tramadol (prolonged release) in 1,832 in the ratio 2:2:2:3 with moderate-to-severe chronic low back pain (CLBP) in North America, EU and Asia for 56 wks.
• The P-III A4091059 study results: well tolerated @56wks.; RPOA (1.4% vs 0.1%); ratio of RPOA type 1 (accelerated joint space narrowing) RPOA type 2 (damage or deterioration of the joint), 6:1; Subchondral insufficiency fracture (0.4%); total joint replacement (0.7%); no events of osteonecrosis
• Tanezumab (5mg, 10mg, SC) is a mAb, NGF inhibitor and has also received FDA’s FT designation in Jun,2017. In 2013, Pfizer and Lilly collaborated to jointly develop and commercialize tanezumab 

Click here to read full press release/ article | Ref: Pfizer | Image: Patient Daily